Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech скачать в хорошем качестве

Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy—as one of the only women of color leading a major pharmaceutical company. This session was recorded on April 23, 2025. Chapters 0:00 Introduction 1:45 Alnylam foundation 4:10 Innovation milestones 7:48 5-year goals 9:32 Managing risk 12:26 Golden era of biotech 13:38 Utilizing AI 15:50 Career journey 17:58 Alnylam culture 22:31 Future of the industry 24:22 Leading Alnylam 26:05 Mentorship 29:10 Conclusion The opinions and views expressed in this program may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. This program should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs. Each name of a third-party organization mentioned in this program is the property of the company to which it relates, is used here strictly for informational and identification purposes only, and is not used to imply any ownership or license rights between any such company and Goldman Sachs. The content of this program does not constitute a recommendation from any Goldman Sachs entity to the recipient, and is provided for informational purposes only. Goldman Sachs is not providing any financial, economic, legal, investment, accounting, or tax advice through this program or to its recipient. Certain information contained in this program constitutes “forward-looking statements”, and there is no guarantee that these results will be achieved. Goldman Sachs has no obligation to provide updates or changes to the information in this program. Past performance does not guarantee future results, which may vary. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in this program and any liability therefore; including in respect of direct, indirect, or consequential loss or damage is expressly disclaimed.